As the subscription date of December 16, 2024 approaches, the IPO of Inventurus Knowledge Solutions (IKS Health) has garnered considerable interest in the market. Backed by famous investor Rekha Jhunjhunwala, this IPO has attracted interest from a wide range of investors, as evidenced by the subscription numbers that show strong demand across categories. This is an in-depth examination of the key features of the IPO, developments in the grey market premium, and professional perspectives.
Read more: Mobikwik IPO date And Price
IKS Health IPO Overview
Healthcare technology company Inventurus Knowledge Solutions Ltd. (IKS Health) was founded in 2006 and focuses on providing administrative support services to healthcare providers in the US, Canada, and Australia. Its solutions, which let healthcare companies focus on their core functions, include revenue cycle management, clinical documentation, and virtual medical scribing.
IPO Details
Details | Information |
Issue Size | ₹2,498 crore |
Price Band | ₹1,265 - ₹1,329 per share |
Subscription Dates | December 12 - December 16, 2024 |
Type of Issue | Offer for Sale (OFS) |
Shares on Offer | 1.88 crore equity shares |
Post-IPO Market Cap | ₹22,802 crore |
Listing Date | December 19, 2024 |
Stock Exchanges | BSE & NSE |
Key Financials and Ratios
Metrics | 2-Year Annual Growth (%) | TTM | FY24 | FY23 | FY22 |
Revenue (₹ crore) | 54.30% | 2,470 | 1,818 | 1,031 | 764 |
EBIT (₹ crore) | 40.40% | 544 | 462 | 305 | 234 |
PAT (₹ crore) | 26.10% | 374 | 371 | 305 | 233 |
Net Worth (₹ crore) | - | 1,377 | 1,158 | 829 | 647 |
Total Debt (₹ crore) | - | 941 | 1,317 | 48 | 59 |
Ratios | 3-Year Average (%) | TTM | FY24 | FY23 | FY22 |
ROE (%) | 38.20% | 33.1 | 37.3 | 41.4 | 36 |
ROCE (%) | 33.10% | 33.6 | 27.6 | 38.5 | 33.2 |
EBIT Margin (%) | 28.60% | 22 | 25.4 | 29.6 | 30.7 |
Debt-to-Equity Ratio | 0.4 | 0.7 | 1.1 | 0.1 | 0.1 |
Strengths of IKS Health
Strong Client Relationships: In FY22-24, repeat business accounted for over 98% of sales, reflecting the company's reliability and customer satisfaction.
Growing Healthcare Expenditure: IKS Health benefits from rising healthcare spending in the US, where 96% of their revenue comes from.
Efficient Operational Model: Its technologically advanced platform reduces customer spending by streamlining healthcare administration.
Shareholding Pre & Post Issue
Weaknesses of IKS Health
Client Concentration Risk: 68% of revenue in H1 FY25 comes from the top 10 customers. If a key customer leaves, overall performance could be impacted.
High Valuation Multiples: With a P/E of 61 and a P/B of 16.6, the IPO is expensive compared to its peers, which raises questions about its prospects for future growth.
Subscription Status as of Day 3
- Retail Individual Investors (RIIs): Subscribed 4.24x
- Non-Institutional Investors (NIIs): Subscribed 3.13x
- Qualified Institutional Buyers (QIBs): Subscribed 1.89x
The total subscription for the IPO stands at 3.19x as of the third day, underscoring its popularity among retail and institutional investors alike.
Expert Analysis and Recommendations
IKS Health operates in a fast-growing sector and has a large market share in healthcare support services thanks to its tech-enabled platform. Consistent growth in sales and profits has strengthened its reputation as a long-term investment.
Despite the company's impressive financial results, cautious investors may shy away from high price multiples. Before investing, one should keep in mind the potential for further growth.
Given its solid GMPs, expanding clientele, and solid financial history, the IPO may attract investors with a long-term outlook and high tolerance for risk. However, those concerned about client concentration concerns and valuations should exercise caution.
Keep following 5 Dariya News for topics like that.